Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 915268 | ISIN: FR0000063737 | Ticker-Symbol: BAQ
Frankfurt
20.01.25
08:04 Uhr
44,900 Euro
+0,050
+0,11 %
Branche
Telekom
Aktienmarkt
Sonstige
1-Jahres-Chart
AUBAY SA Chart 1 Jahr
5-Tage-Chart
AUBAY SA 5-Tage-Chart
RealtimeGeldBriefZeit
45,15046,20020.01.
Actusnews Wire
273 Leser
Artikel bewerten:
(1)

AUBAY: 2024 third-quarter revenue: Acceleration in organic growth (up 4.3% over three months and up 0.7% over nine months)

Finanznachrichten News
In € millionQ3 2024*Q3 2023Organic change9 months 2024*9 months 2023Organic change
France67.464.2+5.0%211.2208.6+1.3%
International61.859.7+3.4%190.3190.1+0.1%
Total129.2123.9+4.3%401.5398.7+0.7%

* Pre-audit figures

In an unchanged economic environment, Aubay posted third-quarter 2024 revenue of €129.2 million, up 4.3% organically. As expected, Aubay has returned to growth thanks to an improved operating performance and a favorable calendar effect. Revenue for the first nine months of the year amounted to €401.5 million, up 0.7%.

France continued to benefit from the resilience of the main markets in which Aubay operates, both with long-standing customers and new key accounts. Third-quarter revenue amounted to €67.4 million, up 5.0% organically.

Internationally, consolidated revenue totaled €61.8 million, up 3.4%. All countries delivered improved performances.

Restructuring efforts in Italy are bearing fruit, with quarterly revenue now stabilized at around €25 million, and sales price increases that have been in place for the past year still ongoing. The savings achieved will be fully measurable in 2025.

Spain and Portugal maintained a good level of growth, fueled by higher sales prices and an improved activity rate. Belgium and Luxembourg reported a slight increase in business over the period.

Sales prices remain on an upward trend, and are now rising in all the regions in which the Group operates. Productivity also improved slightly, reaching 94.3% compared to 93.4% in the same period of 2023.

Management has focused on optimizing margins, leading to a slight decline in the total workforce, to 7,440 at the end of the period. This decline was mainly attributable to Spain and Portugal, where the number of employees waiting between contracts was 2.5 times lower, in line with agile workforce management.

It is worth noting that, after the usual unfavorable seasonal effect in the summer months, all regions returned to positive net recruitment figures in September and October.

Business outlook for the full year

Aubay's business environment has not changed significantly in recent weeks. Under these conditions, the Group confirms that it expects to achieve the targets announced at the start of the year:

  • revenue of between €534 million and €550 million;
  • recurring operating margin between 8.5% and 9.5%.

Aubay will publish its full-year 2024 revenue on Wednesday, January 22, 2025 after the close of trading.

Glossary

Organic revenue growth: this refers to growth calculated for a constant scope of activity for a given period, excluding revenue from companies that were acquired or sold during the period. As Aubay conducts most of its business in the euro zone, any impact from changes in exchange rates is minimal.

Cumulative
9 months 2024
Organic growth+0.7%
Impact of changes in scope0
Growth as reported+0.7%

Operating profit from ordinary activities: this indicator corresponds to operating income before the cost of free shares and other income and expenses that are unusual, significant or infrequent and that are booked separately in order to facilitate understanding of an entity's recurring operating performance.

Operating margin from ordinary activities: this indicator, which is expressed as a percentage, is the ratio of operating income from ordinary activities to revenue.

Net debt or net cash: this indicator represents the difference between an entity's cash and debt. If the result is negative, it is referred to as net debt. If it is positive, it is referred to as net cash.

About Aubay

Aubay is a digital services company working alongside some of the biggest names in the Banking, Finance, Insurance, Manufacturing, Energy, Transport and Telecoms sectors. Aubay has 7,440 employees in seven countries (France, Belgium, Luxembourg, Italy, Spain, Portugal and the United Kingdom). Aubay generated revenue of €513.5 million in 2023.

Euronext, Compartment: B - ISIN FR0000063737-AUB - Reuters AUBT.PA - Bloomberg AUB:FP

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: mpufaJycaGqVx5tylZ6XmZVpZpdnmmiWZmHJlpeZapbIaW9jl2pha5ScZnFpmGpu
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-88358-communique-financier-t3-2024-aubay_veng.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.